Interleukin Genetics Announces Conference Call and Webcast to Discuss 2Q 2008 Business Results
08/06/2008
WALTHAM, MA - August 6, 2008 - Interleukin Genetics, Inc. (AMEX: ILI) announced today that it will host a conference call and webcast on Wednesday, August 13, 2008, at 8:30 a.m. EDT to review the Company's second quarter 2008 financial results and provide an update on recent corporate developments.
To access the live call, dial 877-675-4751 (domestic) or 719-325-4910 (international). The live webcast and replay access of the teleconference will be available on the Investors section of the Company's website at www.ilgenetics.com.
About Interleukin Genetics
Interleukin Genetics, Inc. ILI is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.
  |